A drug-loaded membrane was prepared by electrospinning Polyε-caprolactone (PCL) with doxycycline hydrochloride (DOX) (15–25% w/w). Scanning electron microscopy (SEM) images revealed that fibrous average diameter decreased from 247.16±57.61 nm to 194.43±43.33 nm with the drug proportion increasing from 15% to 20% w/w, while there was no significant difference between 20% and 25% groups. The polymer matrix showed good encapsulation value (58–75%) for DOX, and the drug showed an amorphous manner in the polymer matrix. The agar diffusion test revealed that DOX-loaded membranes had an obvious inhibited effect onAggregatibacter actinomycetemcomitans(Aa) andPorphyromonas gingivalis(Pg), respectively. In vitro release test showed that DOX could persistently be released for a prolonged time more than 28 days, and the DOX level in the eluent steadied at 3–5 μg/mL which was all above the minimum inhibitory concentration (MIC) of DOX against Aa (0.125 μg/mL) and Pg (0.0625 μg/mL). Cytocompatibility, assessed in human periodontal ligament cells (hPLCs) by MTT-test and the morphology of cells on the surface of DOX-loaded membranes by SEM, indicated that all of the investigated nanofibrous membranes can be used to treat periodontal disease by integrating the GTR/GBR operation and antibiotic therapy. Above all, DOX-loaded nanofibrous membranes could have a persistent inhibited effect on periodontal pathogens to provide a relatively sterile environment for tissue repair and regeneration.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: